27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by structural changes of the hippocampus, thus hippocampal morphology becomes an important biomarker for early diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Implementation of an EHR-enabled AD care pathway was associated with improved adoption of guideline-concordant cognitive assessment and recommended diagnostic evaluation in primary care across three health systems. 5 key findings →
Participants: 10,206 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia public stigma was associated with education, dementia knowledge, media exposure, chronic diseases, and contact experience with people living with dementia. 5 key findings →
Design: cross-sectional Participants: 3,055 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with MCI and AD exhibit marked deficits in the performance and accuracy of upper-limb reaching and catching movements when assessed in a VR environment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Medication adherence in older adults was strongly influenced by cognitive impairment, gender, health literacy and cohabitation. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Apathy and depression are among the most common neuropsychiatric symptoms in dementia. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Multimodal integration of cognitive, neuroimaging, and polygenic data in the MHS-RWD tool yields strong discrimination for both early diagnosis of dementia and AD differential diagnosis. 2 key findings →
Participants: 1,100 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings suggest that serum brain-derived p-tau 217 and SV2A are more specific diagnostic biomarkers for reflecting brain damage and may not be disturbed by peripheral damage for AD patients. 5 key findings →
Design: cross-sectional Participants: 1,198 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Detection and characterisation of dementia and Mild Cognitive Impairment (MCI) is essential for diagnosis and to support recruitment of patients into trials of disease-targeted therapies. 1 key finding →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source
We used the September 2013 age-based rollout of the live-attenuated shingles vaccine in England as a natural experiment to estimate the effect of vaccine eligibility on shingles and dementia diagnoses in linked hospital records. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The retina displayed earlier and broader AD-related molecular alterations than the hippocampus. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Structured Abstract Background Alzheimer’s disease (AD) neuropathology emerges decades before symptoms, requiring sensitive, non-invasive markers for early diagnosis. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Functional–behavioral subtypes can be identified in hospitalized AD patients, supporting multidimensional risk stratification and individualized care planning. 2 key findings →
Design: cross-sectional Participants: 118 Evidence: low
Full summary, score breakdown and related studies → Original source
Interventions that reduce functional capacity — antipsychotics or benzodiazepines for agitation, activity restriction for fall prevention, prolonged bed rest, incontinence product use, and catheterization — remain common in nursing homes even though functional decline is measured, publicly reported, and built into Five-Star ratings. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Thorough and structured assessment is essential for identifying unmet needs and managing distress in people with dementia in acute hospitals. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nurses showed moderate knowledge and positive attitudes, with knowledge closely linked to attitudes. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Significant positive correlations were observed among pain, cognitive impairment, agitation, and neuropsychiatric symptoms (all p < 0.001). 4 key findings →
Participants: 107 Evidence: low
Full summary, score breakdown and related studies → Original source
Brexpiprazole was associated with a distinct neuropsychiatric adverse-event reporting pattern in Alzheimer’s disease compared with psychiatric indications, with the most consistent signals observed for delirium, falls, and agitation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Affective symptoms, such as depression, anxiety and apathy, are highly prevalent in cognitively impaired Lewy body disease (LBD) groups, including Parkinson’s disease dementia and dementia with Lewy bodies. 2 key findings →
Design: systematic review Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
In total, 45 constituents were mapped to 181 human target genes through measured compound-target edges. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Agitation days showed higher median sample entropy (1.23 vs 1.06; p<0.001) and approximate entropy (1.24 vs 1.08; p<5 × 10−19). 5 key findings →
Participants: 114 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Default thresholds yielded 20–23% precision with 94– 100% recall—unacceptable for caregiver-facing alerts. 5 key findings →
Participants: 51 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 11,377 AD hospitalizations, 600 in-hospital deaths occurred (5.27%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is variably recorded across routine datasets, and the setting in which dementia is first recorded identifies groups with markedly different prognosis. 1 key finding →
Design: cohort study Participants: 133,407 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Wearable devices may facilitate the measurement and treatment of specific BPSD, as well as reduce caregiver burden. 2 key findings →
Design: cross-sectional Participants: 20 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →